mTHPC-mediated photodynamic treatment of Lewis lung carcinoma in vitro and in vivo

Daiva Dabkevičienė¹, Vaidotas Stankevičius¹, Gražina Graželienė², Arvydas Markuckas¹, Janina Didžiapetrienė², Vida Kirvelienė¹

¹Department of Biochemistry and Biophysics, Vilnius University, ²Institute of Oncology, Vilnius University, Lithuania

Key words: photodynamic treatment; LLC1 cell line; Lewis lung carcinoma; photosensitizer; mTHPC.

Summary. Background and objective. The ongoing search for the enhancement of efficacy of photodynamic therapy stimulates the interest in molecular mechanisms of the response to the treatment. Looking for the cell line suitable for investigation of cellular response both in vivo and in vitro, we evaluated phototoxicity of m-tetrakis-(3-hydroxyphenyl)-chlorin (mTHPC) on viability of Lewis lung carcinoma (LLC1) cells in vitro, growth of murine transplantable tumor, and mice survival.

Material and methods. LLC1 cell culture and male C57BL/6 mice bearing Lewis lung carcinoma were used for the experiments. Photodynamic treatment was mediated by m-tetrakis-(3-hydroxyphenyl)-chlorin as a photosensitizer. Light emitting diode array was used for illumination. The effect of the photodynamic treatment was evaluated by comparison of viability of control and treated cells, growth of tumors, and survival of the control and treated mice.

Results. In vitro, a cytotoxic dose inducing a reduction in viability of LLC1 cells by 50% was achieved at 60 mJ/cm² and approximately 400 ng/mL of the photosensitizer, or 30 mJ/cm² and 600 ng/mL of mTHPC. Both the concentration of the photosensitizer and duration of light exposure were significant determinants of cytotoxic effect. In vivo, an injection of 0.25 mg/kg of mTHPC to mice bearing Lewis lung tumor and illumination at 120 J/cm² taking place after 24 h significantly inhibited tumor growth and prolonged mice survival. However, the tumors regained their growth potential after 9 days.

Conclusions. Photodynamic treatment mediated by m-tetrakis-(3-hydroxyphenyl)-chlorin had a significant effect on LLC1 cells in vitro and growth of Lewis lung carcinoma in vivo.

Introduction

Photodynamic treatment (PDT) is a mode of therapy for eradication of tumors and other formations produced by cell overgrowth. It is based on the excitation of a cell-localized photosensitizer with visible light and the following generation of reactive oxygen species, which induce oxidative damage to cellular components (1). Recent progress in PDT as well as the recorded limitations of the treatment has stimulated attempts to establish details of the molecular mechanism of cellular response to the treatment. It was found that PDT caused overexpression of vascular endothelial growth factor (VEGF) (2) as well as other cytokines (3). Some of them are considered essential for tumor growth and necessary for the spread of tumor cells (4). These findings stimulated the idea to increase the efficacy of PDT by combination with immunotherapy (5). The combination of antiangiogenic and PDT therapy gave the first promising experimental results (6).
In this study, starting the investigation of LLC1 cell response to PDT, we evaluated the efficacy of photodynamic treatment in LLC1 cells and Lewis lung tumors. Neutral lipophilic chlorin derivative m-tetrakis-(3-hydroxyphenyl)-chlorin (mTHPC, generic name Temoporfin, commercial name Foscan®) (10) was used for PDT. It is one of the most potent photosensitizers currently available for clinical use, and it has been successfully applied for treatment of head and neck cancers (11). LLC1 cells as well as the tumors have already been used for PDT studies (12–15); however, to our knowledge, this is the first report of mTHPC-mediated PDT of LLC1 cells in vitro and tumors in vivo.

Materials and methods

Photosensitizer. m-Tetrakis-(3-hydroxyphenyl)-chlorin (mTHPC, kindly provided by R. Bonnett, Queen Mary’s College, the University of London, UK) was dissolved in ethanol as 3-mg/mL stock solution and stored at –20°C in the dark. All experiments in vitro were performed using dilutions of the stock solutions with cell incubation media. For experiments with mice, the stock solutions were diluted with water for injection to a final concentration of 0.25 mg/kg in 0.2 mL for mTHPC.

Cell culture. Culture flasks and Petri dishes were from Techno Plastic Products AG. Fetal calf serum (FCS) was from Gibco BRL. Other tissue culture products were obtained from Sigma. The murine Lewis lung carcinoma 1 cells, LLC1, were obtained from the American Type Culture Collection (ATCC). The cells were cultured in subconfluent monolayer (60–70%) in 25-cm² flasks in the Dulbecco’s minimal essential medium (DMEM) supplemented with 10% FCS, 100 IU/mL penicillin, 100 µg/mL streptomycin, and 2 mM glutamine at 37°C in 5% CO₂ atmosphere. The cells were subcultured by dispersal with 0.025% trypsin in 0.02% EDTA and replaced at 1:6 dilutions three times a week.

Mice. Male C57BL/6 mice (the facility of Immunology Institute, Lithuania) at 8–10 weeks of age and 22–25 g body weight were used throughout the study. The animals received care in accordance with the guidelines established by the Lithuanian Animal Care Committee, which approved the study.

Cell exposure to photodynamic treatment. Cell exposure to a photosensitizer and light was carried out in 9.2-cm² Petri dishes according to the experimental scheme shown in Fig. 1, part A. The cells were seeded out as a suspension in DMEM supplemented with 10% FCS at a density of 0.7×10⁵ cells/mL in 1.85 mL per dish. After 30 h, mTHPC was added to the cell monolayer in log phase to a final concentration of 100, 200, 400, or 600 ng/mL. When handling the samples containing mTHPC, precautions were taken to avoid irradiating the samples with room light by reducing the sources of illumination to a minimum and by protecting the samples from light with aluminum sheets. After incubation for 18 h at 37°C in the dark, an extracellular photosensitizer was removed by rinsing the cell monolayer 2 times with room temperature DPBS, and DMEM containing 10% FCS was added. The cells were exposed to light from an LED array UNIMELA-1 (λ=660±20 nm, VU Laser Research Center, Lithuania) for 0.5 and 1.0 min, the fluence rate at the level of the cells being 1 mW/cm², as measured using an IMO (Russia). After light exposure, the cells were incubated for 24 h until cell viability was estimated.

Fig. 1. Scheme for treatment of cells (A) and mice (B)

A, 100–600 ng/mL of mTHPC was added to LLC1 cells and incubated in the dark for 18 h. Then the incubation medium was replaced with the fresh one, and the cells were exposed to light at λ=660±20 nm, 1 mW/cm², and the cells were incubated for 24 h postexposure; B, mTHPC, 0.25 mg/kg, was injected intravenously to mice bearing subcutaneous Lewis lung carcinoma. After 24 h, the mice were exposed to laser illumination at 650±2 nm, 120 J/cm². During following 13 days, tumor volume was measured every two or three days. The survival of mice was observed every day until demise.
Photodynamic treatment of Lewis lung carcinoma

Cell viability assessment. For the assessment of cell viability, tetrazolium dye 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was used. Briefly, the cells were incubated with MTT for 1 h at 37°C. Then, the MTT solution was discarded, and the blue dye was extracted with 1 mL of 2-propanol. The optical density (OD) was then recorded at 570 nm using an ASYS UVM 340 microplate reader. The mean OD, of the control cells exposed to test compound-free culture medium was set to represent 100% of viability, and the results were expressed as a percentage of these controls (16).

Tumor inoculation and observation. Mice were injected subcutaneously with 0.2 mL of 5-time diluted suspension of Lewis lung tumor mass in the right groin. Tumor volume (TV) was determined by measuring the tumor diameter with vernier calipers and calculating according to the formulae:

\[ TV = L \times W \times H \times \pi / 6, \]

where L is length, W is width, and H is height of the tumor. After tumor exposure to treatment, tumor growth was monitored three times per week for up to 13 days, and survival was recorded daily throughout the experiment. The antitumor activity was evaluated by the index of tumor growth inhibition (TGI) in treated (T) vs. control (C) mice, which was calculated according to the formulae TGI = 100 – (TV_T / TV_C × 100).

Tumor exposure to treatment. For evaluation of antitumor activity, mice were treated according to the experimental schedule shown in Fig. 1, part B. mTHPC was administered 10 days after transplantation when tumor volume was 94±31 mm³. Mice were coded and randomized into two groups (n=6 in each group): group 1, control mice and group 2, PDT-treated mice. In the group 1, mice were not treated. In the group 2, PDT was performed as follows: 0.2 mL of mTHPC was injected intravenously at a dose of 0.25 mg/kg, and after 24 h, tumors were exposed to light from the diode laser (Institute of Oncology, Vilnius University, Lithuania) at 650±2 nm wavelength and fluence rate of 135 mW/cm² for 15 min, reaching a dose of 120 J/cm².

Data analysis. Results were expressed as the mean ± standard error. The data of experiments in vitro were analyzed using two-way ANOVA. Significance of the volume differences between two groups of tumors was assessed by t test. The Kaplan-Meier method was used for the survival analysis. The level of significance of the differences between the survival curves was assessed by the Gehan-Breslow test. Statistical significance was set at P<0.05. SigmaPlot 10 software was used for the statistical analysis.

Results
The effect of PDT in vitro was characterized by the dose-response relationship of cytotoxicity measured by reduction of cell viability at 24 h post-exposure. The cells were preincubated in the medium containing 100–600 ng/mL of mTHPC and exposed to light for 0.5 or 1 min at a fluence rate of 30 and 60 mJ/cm², respectively. The residual viability of the cells was assessed by the MTT assay, which is a reliable cytotoxicity test for photodynamically treated cells (17). Neither cytotoxicity of the photosensitizer at the selected concentration without light exposure nor that of light without mTHPC photosensitization was registered. CD50, a cytotoxic dose inducing a reduction in cell viability by 50%, was achieved at 60 mJ/cm² and approximately 400 ng/mL of mTHPC, or 30 mJ/cm² and 600 ng/mL of mTHPC (Fig. 2). The contribution of the treatment factors to the overall result was evaluated by the two-way analysis of variance. The analysis revealed that both concentration of mTHPC and duration of light exposure in the presence of mTHPC were significant determinants of the cytotoxic effect of PDT on LLC1 cells in vitro (Table 1).

In mice bearing Lewis lung tumor, we investigated the effects of PDT in vivo following the injection of 0.25 mg/kg of mTHPC and illumination at 120 J/cm² taking place after 24 h. The experimental conditions were established during a series of pilot experiments and found to be optimal. The results showed that PDT significantly inhibited tumor growth and prolonged survival of mice as compared to control mice. The effect of PDT was dose-dependent, and the optimal dose for tumor inhibition and survival was found to be 0.25 mg/kg mTHPC and 120 J/cm², respectively. The results were consistent with the in vitro findings, indicating that the in vivo effect of PDT is mediated by the photodynamic mechanism and is dependent on the dose of mTHPC and the fluence of the light used for treatment.

Table 1. Significance of the cytotoxic effect of treatment factors

| Treatment factor | F ratio | P       |
|------------------|---------|---------|
| Light exposure   |         | <0.001  |
| mTHPC            | 76      | <0.001  |

Fig. 2. Viability of LLC1 cells after mTHPC-mediated photodynamic treatment

The cells were incubated with mTHPC as shown in Fig. 1 and exposed to light at 660±20 nm and 1 mW/cm². Cell viability was evaluated by the MTT assay following incubation for 24 h in the dark. Error bars represent SE.
experiments (data not shown). In addition, the pilot experiments revealed the absence of antitumor activity of light without mTHPC or mTHPC without light. Tumor volumes of the treated mice were smaller than those in the control group, as shown in Fig. 3A, and the difference was significant (Table 2). The most pronounced inhibition of tumor growth, exceeding 80%, was registered on days 3 to 9 (Fig. 3B).

The survival of the treated mice corresponded with tumor growth inhibition: the treated mice survived for a longer time than those in the control group (Fig. 4), and the difference was significant ($P=0.025$).

**Discussion**

Mouse tumor models have been extensively employed in preclinical studies investigating various aspects of host-tumor interaction following anticancer treatment. One of them is Lewis lung carcinoma, which has been widely used as a model for studying the mechanisms of cancer chemotherapeutic agents. In preclinical PDT studies, Lewis lung carcinoma has been used for investigations in vitro and in vivo involving various photosensitizers, such as porphyrin (12, 13), ALA (14), and phthalocyanines (15). Singlet oxygen is the main reactive oxygen species (ROS), produced by PDT. It induces spatially resolved responses in a cell (18). Thus, cell response depends on the site of ROS production, i.e. subcellular localization of the photosensitizer. Since the pattern of photosensitizer accumulation by the cells is unique to a photosensitizer, in our study on mTHPC-mediated PDT, we could not rely on the
published LLC1 cell response to PDT, mediated by other photosensitizers.

The results of this study support our suggestion that Lewis lung carcinoma model is relevant for investigation of cellular response to mTHPC-mediated PDT, since both the cells in vitro and tumors in vivo were damaged by the treatment. LLC1 cells lost their viability in vitro following mTHPC-mediated photodynamic treatment at a significantly lower dose of the photosensitizer and significantly lower light exposure than in the case of ALA-mediated PDT in vitro (14). The main problem with the LCC1 cells is their weak attachment to the growth substrate and the need to be careful in dealing with the cultivation dishes.

The effect of mTHPC-mediated PDT on Lewis lung carcinoma in vivo was prominent and exceeded that of Photofrin-mediated PDT in vivo (13). The pattern of tumor growth inhibition by mTHPC-mediated PDT revealed the dual character of Lewis lung carcinoma response. During the first 9 days post-exposure, the tumor growth was inhibited at a great extent. However, afterward the tumors regained their growth potential, and the growth seemed to be even accelerated in comparison with the tumors in untreated mice. The recurrence of tumor growth could be the consequence of the overexpression of cell/tumor proliferation-promoting cytokines, secreted by insulted tumor cells. This suggestion is the scope of our future investigation.

**Conclusions**

The photodynamic treatment mediated by m-tetrakis-(3-hydroxyphenyl)-chlorin had a significant effect on Lewis lung carcinoma both in vivo and cells in vitro. The tumors, which growth was inhibited by photodynamic treatment, regained their growth potential in approximately a week.

**Acknowledgments**

We thank Raymond Bonnett (Queen Mary, University of London, UK) for a generous gift of mTHPC, and Vida Piskarskienė for excellent care of the cells. This work was supported by the Lithuanian State Foundation for Science and Studies, project T-77/08.
References

1. Juzeniene A, Peng Q, Moan J. Milestones in the development of photodynamic therapy and fluorescence diagnosis. Photochem Photobiol Sci 2007;6:1234-45.

2. Uehara M, Inokuchi T, Sano K, ZuoLin W. Expression of vascular endothelial growth factor in mouse tumors subjected to photodynamic therapy. Eur J Cancer 2001;37:2111-5.

3. Gollnick SO, Evans SS, Baumann H, Owczarczak B, Maier P, Vaughan L, et al. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br J Cancer 2003;88:1772-9.

4. Slaton JW, Millikan R, Inoue K, Karashima T, Czerniak B, Shen Y, et al. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol 2004;171:570-4.

5. Kwitniewski M, Juzeniene A, Glosnicka R, Moan J. Immunotherapy: a way to improve the therapeutic outcome of photodynamic therapy? Photochem Photobiol Sci 2008;7:1011-7.

6. Tirand L, Frochot C, Vanderesse R, Thomas N, Trinquet E, Pinel S, et al. A peptide competing with VEGF(165) binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photodynamic activity in human endothelial cells. J Control Release 2006;111:153-64.

7. Kirveliene V, Graželiene G, Dabkevičienė D, Mickė I, Kirvelis D, Juodka B, et al. Schedule-dependent interaction between Doxorubicin and mTHPC-mediated photodynamic therapy in murine hepatoma in vitro and in vivo. Cancer Chemother Pharmacol 2006;57:65-72.

8. Sasnauskienė A, Kadziauskas J, Vežžytė N, Jonušienė V, Kirveliienė V. Apoptosis, autophagy and cell cycle arrest following photodamage to mitochondrial interior. Apoptosis 2009;14:276-86.

9. Bertram JS, Janik P. Establishment of a cloned line of Lewis lung carcinoma cells adapted to cell culture. Cancer Lett 1980;11:63-73.

10. Bonnett R, White RD, Winfield UJ, Berenbaum MC. Hydrophyrins of the meso-tetra(hydroxyphenyl)porphyrin series as tumor photosensitizers. Biochem J 1989;261:277-80.

11. Dílkes MG, Benjamin E, Ovaisi S, Banerjee AS. Treatment of primary mucosal head and neck squamous cell carcinoma using photodynamic therapy: results after 25 treated cases. J Laryngol Otol 2003;117:713-7.

12. Stott B, Korbelik M. Activation of complement C3, C5, and C9 genes in tumors treated by photodynamic therapy. Cancer Immunol Immunother 2007;56:649-58.

13. Akramiène D, Graželiene G, Didziapetriene J, Kevelaitis E. Treatment of Lewis lung carcinoma by photodynamic therapy and glucan from barley. Medicina (Kaunas) 2009;45:480-5.

14. Skivka LM, Gorobets OB, Kutsenok VV, Lozinsky MO, Borisevich AN, Fedorchuk AG, et al. 5-aminolevulinic acid mediated photodynamic therapy of Lewis lung carcinoma: a role of tumor infiltration with different cells of immune system. Exp Oncol 2004;26:312-5.

15. Karmakova T, Feofanov A, Nazarova A, Grichine A, Yakubovskaya R, Luk’yanets E, et al. Distribution of metal-free sulfonated phthalocyanine in subcutaneously transplanted murine tumors. J Photochem Photobiol B 2004;75:81-7.

16. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. J Immunol Methods 1986;89:271-7.

17. Mickuviene I, Kirveliene V, Juodka B. Experimental survey of non-clonogenic viability assays for adherent cells in vitro. Toxicol in Vitro 2004;18:639-48.

18. Redmond RW, Kochevar IE. Spatially resolved cellular responses to singlet oxygen. Photochem Photobiol 2006;82:1178-86.

Received 10 February 2009, accepted 7 May 2010

Straitspnis gautas 2009 02 10, priimtas 2010 05 07